A NEW SET OF PSYCHEDELIC MEDICINES
Dedicated to improving human health
through groundbreaking innovations
in psychedelic therapeutics.

Mission

WE ARE CREATING TRANSFORMATIVE MEDICINES TO
ADDRESS BIG PROBLEMS IN SOCIETY

The number of people with diabetes has increased by over 300 million since 1980. That number continues to rise. Diabetes is a major cause of kidney failure, blindness, stroke, heart attacks, and lower limb amputation. Conventional treatments are not working, we need an innovative approach.

The global prevalence of obesity has nearly tripled since 1975. Over 650 million adults worldwide are obese. Obesity is a major risk factor for diabetes, cardiovascular diseases, osteoarthritis, and some cancers. Mental health plays a key role as a cause and consequence of obesity and needs to be addressed in novel treatments for sustained results.


Notice: WP_Scripts::localize was called incorrectly. The $l10n parameter must be an array. To pass arbitrary data to scripts, use the wp_add_inline_script() function instead. Please see Debugging in WordPress for more information. (This message was added in version 5.7.0.) in /home/novament/public_html/wp-includes/functions.php on line 5313

Stock Data

Here you will find the most recent Stock Data for Nova Mentis Life Science Corp. (CSE: NOVA)

 
Prev. Close  
MARKET CAP:
 
CHANGE:
 

Press Releases

BE FIRST TO KNOW WHAT IS HAPPENING IN OUR COMPANY

LATEST NEWS
See All
Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

Vancouver, British Columbia – September 14, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary …

READ MODE
Nova Mentis to Present at the H.C. Wainwright Global Investment Conference

Vancouver, British Columbia – September 9, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary …

READ MODE
Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

Vancouver, British Columbia – September 7, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary …

READ MODE

Contact Us